- Open Access
Mortality predictors of Staphylococcus aureus bacteremia: a prospective multicenter study
- Mesut Yilmaz1Email authorView ORCID ID profile,
- Nazif Elaldi2,
- İlker İnanç Balkan4,
- Ferhat Arslan1,
- Ayşe Alga Batırel5,
- Mustafa Zahir Bakıcı3,
- Mustafa Gokhan Gozel2,
- Sevil Alkan6,
- Aygül Doğan Çelik6,
- Meltem Arzu Yetkin7,
- Hürrem Bodur7,
- Melda Sınırtaş8,
- Halis Akalın9,
- Fatma Aybala Altay10,
- İrfan Şencan10,
- Emel Azak11,
- Sibel Gündeş11,
- Bahadır Ceylan1,
- Recep Öztürk4,
- Hakan Leblebicioglu12,
- Haluk Vahaboglu13 and
- Ali Mert1
© Yilmaz et al. 2016
Received: 1 December 2015
Accepted: 1 February 2016
Published: 9 February 2016
Staphylococcus aureus is one of the causes of both community and healthcare-associated bacteremia. The attributable mortality of S. aureus bacteremia (SAB) is still higher and predictors for mortality and clinical outcomes of this condition are need to be clarified. In this prospective observational study, we aimed to examine the predictive factors for mortality in patients with SAB in eight Turkish tertiary care hospitals.
Adult patients with signs and symptoms of bacteremia with positive blood cultures for S. aureus were included. All data for episodes of SAB including demographics, clinical and laboratory findings, antibiotics, and outcome were recorded for a 3-year (2010–2012) period. Cox proportional hazard model with forward selection was used to assess the independent effect of risk factors on mortality. A 28-day mortality was the dependent variable in the Cox regression analysis.
A total of 255 episodes of SAB were enrolled. The median age of the patients was 59 years. Fifty-five percent of the episodes were considered as primary SAB and vascular catheter was the source of 42.1 %. Healthcare associated SAB was defined in 55.7 %. Blood cultures yielded methicillin-resistant S. aureus (MRSA) as a cause of SAB in 39.2 %. Initial empirical therapy was inappropriate in 28.2 %. Although overall mortality was observed in 52 (20.4 %), 28-day mortality rate was 15.3 %. Both the numbers of initial inappropriate empirical antibiotic treatment and the median hours to start an appropriate antibiotic between the cases of fatal outcome and survivors after fever onset were found to be similar (12/39 vs 60/216 and 6 vs 12 h, respectively; p > 0.05). High Charlson comorbidity index (CCI) score (p = 0.002), MRSA (p = 0.017), intensive care unit (ICU) admission (p < 0.001) and prior exposure to antibiotics (p = 0.002) all were significantly associated with mortality. The Cox analysis defined age [Hazard Ratio (HR) 1.03; p = 0.023], ICU admission (HR 6.9; p = 0.002), and high CCI score (HR 1.32; p = 0.002) as the independent predictive factors mortality.
The results of this prospective study showed that age, ICU stay and high CCI score of a patient were the independent predictors of mortality and MRSA was also significantly associated with mortality in SAB.
Staphylococcus aureus is a leading cause of both community and healthcare -associated bacteremia and competes with Escherichia coli for the leading cause of community-acquired bacteremia. S. aureus bacteremia (SAB) can seed to virtually any body site and result in complications that may further result in severe disease, significant morbidity and death .
SAB places a substantial burden on health care systems with its high mortality rates of around 20–30 % and morbidity rates [2, 3]. This burden is increased by life-threatening complications, including infective endocarditis (IE) and other serious metastatic infections complications that more frequently require intensive care unit (ICU) admission and carry poor prognosis because of the anatomic site or the difficulty in reaching a timely diagnosis [4–6]. It is therefore imperative to know which patients are prone to SAB and its complications, variation of laboratory findings during SAB and its predictors of mortality.
Data regarding the characteristics of SAB in Turkey is insufficient and most of them are retrospective character [7–9]. For this reason, this prospective multicenter observational study aimed to identify predictors of mortality in patients with SAB in Turkish hospitals. The most common sources of SAB, its complications, and treatment responses to various antistaphylococcal agents were also investigated.
Study design and patients
This prospective, multicenter cohort study involved a 3-year period from January 2010 to December 2012. A thorough patient data collection form was sent and data were collected prospectively from eight participant centers in Turkey. All consecutive patients (15 years and over) with signs and symptoms of bacteremia with positive blood cultures for S. aureus were included in this study. Only the first clinically significant episode of infection with SAB for each patient was included in the analysis. Patients who had SAB as part of a polymicrobial bloodstream infection were excluded. Clinical Research Ethics Committee of Medipol University (Istanbul, Turkey) approved this study.
Clinical and laboratory analyses and follow-up period
Patients with SAB were identified from microbiology laboratory records by daily visits. Patients were followed in the participant centers until discharge or death. Baseline characteristics, treatment regimens, outcome and other factors were recorded prospectively.
Usually two or more sets of blood cultures were obtained simultaneously from different sites and repeated when needed. Blood specimens were cultured on vials of automatic systems for a 7-day period in different centers, mainly by the BACTEC 9240 system (Becton–Dickinson, Maryland, USA). All S. aureus isolates were identified by standard laboratory methods at the clinical microbiology laboratory of participating centers. Antimicrobial susceptibilities of the isolates including oxacillin and vancomycin were determined by using disk diffusion test or automated systems according to the criteria of the Clinical and Laboratory Standards Institute (CLSI) . During the study period all S. aureus isolates were submitted to the microbiology laboratory of Istanbul Medipol University for further verification. The identification and antimicrobial susceptibilities of isolates were performed by using Vitek 2 (bioMérieux, Marcy L’E`toile, France) bacterial identification and antimicrobial susceptibility testing (AST) system. Other specimens including pus, wound swabs, sputum, tracheal aspirates, bronchoalveolar lavage fluid, synovial fluid and central venous catheter (CVC) tips were also cultured to determine the source of SAB when necessary.
In order to determine the involvement of the cardiovascular system, transthoracic echocardiography (TTE) was performed for all patients when blood cultures were positive for S. aureus. Transesophageal echocardiography (TEE) was also performed for patients suspected of IE with negative TTE findings. Routine laboratory analyses and chest X-rays were also performed for all patients. The validated Charlson comorbidity index (CCI) score, which stratifies the associated diseases into an ordinal scale, was used to evaluate comorbidity in 28-day mortality among the patients . Empirical antibiotic treatment was initiated following the diagnosis of infection and modified when needed.
Bacteremia was defined as the presence of ≥1 positive blood culture for S. aureus in a patient who had signs and symptoms consistent with an infection . SAB was classified as community-acquired if S. aureus was isolated from blood cultures drawn within 48 h of admission of a patient with suggestive symptoms or signs of an infection after hospital admission, if the patient was not transferred from another hospital, and if the patient had any symptoms or signs suggestive of infection at admission. Otherwise, SAB was considered to have been health-care associated . In the presence of a laboratory-confirmed bloodstream infection, primary bacteremia was considered if the organism cultured from blood is not related to an infection at another site. Otherwise, bacteremia was considered secondary. The diagnosis of Systemic Inflammatory Response Syndrome (SIRS) was made according to the criteria of the Surviving sepsis campaign and the presence of SIRS accompanied by infection was diagnosed as sepsis . Prior admission history was defined as hospitalization within 90 days before the onset of SAB.
Foci of bloodstream infection
The primary foci of infection were determined using the following definitions. Catheter-related bloodstream infection (CR-BSI) was defined as SAB in any patient who has an intravascular device with ≥1 positive blood culture result obtained from the peripheral vein and no apparent source for SAB except the catheter. A microbiological proof of a catheter infection was warranted as either a positive result of a semiquantitative (>15 cfu per catheter segment) catheter culture whereby the same organism is isolated from a catheter segment and a peripheral blood culture, or a differential time to positivity (>2 h between catheter vs peripheral blood). Soft tissue infection was considered the source of SAB in cases where patients (a) had a culture of S. aureus from a tissue or a drainage specimen from the affected site and (b) had signs of infection . Surgical site infection was defined according to the definitions of the Centers for Disease Control and Prevention (CDC) .
Antibiotic treatment and outcome
Empirical antibiotics were prescribed by the primary care physician. Appropriate antibiotic treatment was considered if the empirical therapy provided after the onset of bacteremia symptoms included at least one antibiotic to which the isolate was susceptible (a glycopeptide or a lipopeptide for methicillin resistant S. aureus (MRSA); beta-lactam/beta-lactamase inhibitor (BL/BLI) combination or cefazolin for methicillin susceptible S. aureus (MSSA).
De-escalation of antibiotic treatment was defined as a switch to a narrower spectrum agent and it was considered when an antibiotic with activity against MRSA was replaced by an antibiotic with activity against MSSA. Escalation of antibiotic treatment was defined as either the addition of a new antibiotic or a switch on an agent with MRSA activity.
The primary endpoint of this study was 28-day all-cause in-hospital mortality. Bacterial eradication was defined as the absence of S. aureus in repeated blood cultures during therapy and no evidence of recurrent SAB during a follow-up of 28 days, bacterial recurrence was defined as clinical resolution of signs and symptoms of infection during therapy but recurrent SAB during follow-up period. Treatment failure was defined as continuation of signs and symptoms of infection despite therapy or death.
Statistical analysis was performed with Stata 13.1 (Stata Corp. LP, USA). Descriptive statistics such as means, standard deviation, medians, interquartile ranges (IQRs), frequencies, and percentages were collected. Comparisons between the continuous variables were performed using independent-samples t tests or Mann–Whitney U tests as appropriate, while comparisons between categorical variables were performed by Pearson’s Chi squared or Fisher’s exact tests. Cox proportional hazard model was used to assess the independent risk factors on mortality. Variables that have a significance value equal or less than 0.1 in the univariate analysis or variables that have been reported significant in the literature were included in the Cox proportional hazard analysis. Proportionality was controlled. Relative risks (RRs) and hazard ratios (HRs) with corresponding 95 % confidence intervals (95 % CIs) were calculated in order to describe the strength and direction of the association. Difference according to ICU stay was assessed by Kaplan–Meier survival curves and log-rank test. All statistical tests were two-tailed and a p value of <0.05 was accepted as statistically significant.
Epidemiologic and descriptive data
Descriptive characteristics of the cohort (N = 255)
Age >65 years
Chronic renal failure
Immunosuppressive therapy in last 3 monthsa
Chronic obstructive pulmonary disease
Congestive heart failure
Fever (≥38 °C)
Tachycardia (>100 beats/min)
Tachypnea (>20 breaths/min)
Hypotension (arterial tension <90 mmHg)
Peripheral venous catheter
Central venous catheter
Intensive care unit admission
Prior antibiotic used
Prior cardio-pulmonary resuscitation
Leukocytosis (WBC count >10,000/mm3)
Thrombocytopenia (platelet <150,000/mm3)
Leukopenia (WBC <4000/mm3)
Of the 255 patients, 100 (39.2 %) had MRSA bacteremia and 155 (60.8 %) had MSSA bacteremia. One hundred forty-one patients (55 %) were considered as primary SAB. Of all remaining 114 (45 %) patients with secondary SAB; 48 (42.1 %) patients were diagnosed as CR-BSI, 30 (26.3 %) patients were diagnosed as skin and soft tissue infection (SSTI), 18 (15.8 %) were diagnosed as IE, and the remaining 18 (15.8 %) were diagnosed as surgical site infections (SSIs) (Data not shown).
Microbiological and routine laboratory characteristics
Comparison of routine laboratory parameters for fatal and survivor (28-day mortality) patients with Staphylococcus aureus bacteremia measured at the time of blood culture collection
(N = 39)
(N = 216)
Median (IQR) highest WBC (×109/L)
18.8 (11.7, 23.4)
13.7 (10, 17.9)
14 (10, 18.8)
Median (IQR) lowest WBC (×109/L)
8.8 (4.1, 13.3)
7.2 (5.4, 9.5)
7.3 (5.4, 9.6)
Mean ± SD (range) lowest platelet (×109/L)
110 ± 94 (17–461)
196 ± 102 (5–545)
181 ± 106 (5–545)
Mean highest ± SD (range) BUN (mg/dL)
90 ± 72.2 (23–332)
65 ± 59.2 (7–383)
69.1 ± 61.8 (7–383)
Mean highest ± SD (range) creatinine (mg/dL)
2.1 ± 1.9 (0.3–6.7)
2.1 ± 2.5 (0.1–13.5)
2.1 ± 2.4 (0.1–13.5)
Mean highest ± SD (range) ALT (IU/L)
84.0 ± 246.6 (3–1497)
60.6 ± 106.5 (5–1160)
64.3 ± 137.6 (3–1497)
Mean highest ± SD (range) AST (IU/L)
177 ± 724 (6–4391)
69.2 ± 152.7 (6–1157)
86.1 ± 318.3 (6–4391)
Mean highest ± SD (range) GGT (IU/L)
106 ± 106.2 (6–422)
92.7 ± 111.3 (6–757)
94.5 ± 110.4 (6–757)
Mean highest ALP ± SD (range) (U/L)
177.6 ± 189 (46–686)
139.4 ± 119.8 (28–923)
144.2 ± 130.2 (28–923)
Mean lowest ± SD (range) albumin (g/dL)
2.5 ± 0.7 (1.1–4.6)
2.9 ± 0.6 (1.4–4.8)
2.8 ± 0.7 (1.1–4.8)
Median (IQR) highest CRP (mg/L)
191.5 (131, 215)
171 (89, 218)
174 (101, 218)
Characteristics of fatal and survivor patients
Comparison of variables between survivor and patients with fatal outcome (28-day mortality) (N = 255)
(n = 39)
(n = 216)
Median (IQR) age (years)
62 (53, 70)
59 (44, 70)
Gender, n (%)
Median (IQR) time to appropriate antibiotic after fever onset (hours)
6 (2, 30)
12 (2, 27)
Inappropriate empirical antibiotic
Comorbid condition, n (%)a
Charlson comorbidity index score, n (%)
Methicillin-resistant S. aureus, n (%)
Intensive care unit stay, n (%)
Exposure to antibiotics, n (%)b
Complications of bacteremia
SAB resulted in complications in 24 (9.4 %) patients. Nine (37.5 %) patients developed pneumonia, 4 (16.7 %) patients developed vertebral osteomyelitis, 1 (4.2 %) patient developed splenic abscess, and one patient (4.2 %) developed endophthalmitis. The remaining 9 (37.5 %) patients developed other metastatic suppurative complications. Four patients showed a recurrence of bacteremia following cessation of treatment.
Treatment and outcome
Comparison of survivor and fatal patients with Staphylococcus aureus bacteremia in regards to empirical antibiotic treatments and modifications (60-day mortality) (N = 255)
(N = 52)
(N = 203)
[95 % CI]
Empirical treatment options
Appropriate empirical antibiotic use with respect to oxacillin susceptibility and outcome of Staphylococcus aureus bacteremia (28-day mortality)
Oxacillin-resistant (N = 100)
Oxacillin-susceptible (N = 155)
Cox proportional hazard model for 28-day mortality
[95 % CI]
Age (per year increase)
Intensive care unit stay
Time to appropriate antibiotic after fever onset (hours)
Exposure to antibioticsa
Methicillin-resistant S. aureus
Charlson comorbidity index score
Staphylococcus aureus bacteremia is a common and serious infection with significant morbidity and mortality, especially in ICU patients . It is difficult to determine the exact incidence of SAB, since prospective population-based surveillance studies are infrequently performed. The annual incidence has been reported as low as 19.7/100,000 population in Canada and 26/100,000 population in Sweden [17–19], and as high as 50/100,000 population in the USA . The difference could be due to infection control practices or variances in surveillance systems. Interestingly, the incidence of SAB has generally been reported to be higher for males than for females, while some studies have shown an increased mortality for females [20, 21]. Sixty-two percent of our cohort was men and the mortality of SAB in men and women were 16.4 % and 13.5 %, respectively. We have not detected any gender difference in regard to outcomes.
The SAB episodes due to MSSA is generally predominate, especially in countries with a low prevalence of MRSA [17, 22]. Likewise, 60.8 % of our patients turned out MSSA when consecutive 255 patients with SAB were collected. Mortality of SAB has been reported to be declining steadily throughout the 20th century, probably as a result of greater understanding of SAB management. Case-mortality associated with hospital-acquired and community-acquired SAB showed rate reductions of 43 and 23 %, respectively between 1981 and 2000 (p = 0.0001) . A previous prospective study suggests 30-day all-cause mortality of 20.6 % which is significantly associated with older age, and MRSA infection as we found in the cohort . A recent prospective study that included patients with both community and healthcare-associated SAB between 2007 and 2011 reported 30-day all-cause and infection-related mortalities of 25.8 and 11.2 %, respectively . Our cohort showed 28-day all cause and infection-related mortalities of 15.3 and 10.2 %, respectively which may suggest that mortality of SAB may be further decreasing. However, prospective data from larger cohorts are required to resolve this issue. Age has been confirmed as a strong independent predictor of mortality in many studies as we found [23, 25, 26]. The mortality rate was found to be increased from 6 % in young individuals (<15 years old) to 57 % in adults older than 85 years of age by Lamagni et al. .
It is well known that presence of comorbidities can influence the patient outcome. The SAB mortality has been accepted to increase with the presence of one or multiple comorbidities including immunosuppression, cirrhosis, malignancy, and chronic renal failure [17, 27–29]. This study showed that the number of patients having a minimum of one comorbid condition between the fatal and survivor groups were the same. However CCI scoring for the assessment of the severity of illness indicator  revealed that cases with fatal outcome had significantly high CCI score suggesting these cases had more severe illness. However, other studies detected any difference in outcomes for patients with comorbidities [30–34].
Ninety-five percent of MRSA were isolated from healthcare-associated SABs, while 70 % of MSSA were isolated from community-acquired SABs in our cohort. According to current cohort studies, the setting of SAB onset, whether health-care associated or community-acquired, does not seem to have an effect on patient outcomes [12, 34, 35]. Likewise, we were not able to show any difference in mortality rates based on the setting of SAB onset. However, advent of community acquired (CA)-MRSA may change the equation, which remains to be shown in future studies. Currently CA-MRSA isolates are very rarely reported in Turkey .
Patients with SAB developing sepsis or septic shock have mortality rates of ranging between 38 and 86 %, and are strongly associated with worse outcomes [32, 37]. Eighty (31.4 %) patients developed severe sepsis or septic shock in our cohort and 28-day mortality was 32.5 % for such cases. A previous retrospective Turkish study from a single center reported 41.7 % of mortality rate for patients with septic shock .
The impact of methicillin resistance on mortality of SAB has been examined by a number of studies. The results of the majority of these studies are conflicting. A well-designed meta-analysis by Cosgrove et al.  showed that mortality rates for MRSA bacteremia were significantly higher than that of MSSA bacteremia (OR, 1.93; 95 % CI, 1.54–2.42; p < 0.001). Methicillin resistance was found to be an independent risk factor of mortality in our cohort. This finding could be explained by differences in empirical prescribing  or poor vancomycin efficacy . However, a recent study by Wolkewitz et al.  showed that there is only a small and statistically insignificant difference between mortality rates of MRSA and MSSA bacteremia when length of hospital stay was adjusted. Similarly a large prospective study by Melzer et al.  also revealed that MRSA bacteremia was not associated with increased mortality after adjustments for various host confounders including comorbidities, age, and severity of illness.
Heteroresistant vancomycin-intermediate S. aureus (hVISA) should also be considered as a factor for SAB mortality. Although mortality rate of SAB due to hVISA has been reported as high as 75 % in earlier studies , overall, hVISA bacteremia is not associated with an increased mortality rate . One of the limitations in our study was that antimicrobial susceptibility testing for all S. aureus isolates was performed by disk diffusion or commercial automated systems, which tend to undercall resistance . Therefore we are not able to discuss any effect of hVISA on mortality of our patients.
Complications of SAB are common, occurring at rates that range from 11 to 53 % [6, 47]. A recent study evaluating predictive factors associated with the development of metastatic infection following SAB revealed a delay in appropriate antimicrobial treatment of >48 h, persistent fever for >72 h after starting antibiotic treatment and lowest CRP levels of >3 mg/dL as significant in multivariate analysis . Some complications more frequently require intensive care admission and carry poor prognosis because of the anatomic site or the difficulty in reaching a timely diagnosis.
Staphylococcus aureus is one of the only causes of IE in structurally normal heart valves , and it is the leading cause of IE in several countries . A large-scale prospective, multicenter, observational study showed that 13 % of patients with SAB had IE . We found a similar incidence of 15.8 % in our study. Patients with hospital-acquired SAB have a lower incidence of IE than those with community-acquired SAB (2–17 %) as expected .
For the management of SAB, no antimicrobial agent was shown to result in better patient outcomes and the initial therapy was inappropriate in 28.2 % of 255 SAB episodes in our cohort. This was an unexpected observation because inappropriate antibiotic treatment was identified as an independent predictive factor for mortality, as in previous studies [32, 33]. A previous study performed in 819 MRSA bacteremia episodes showed that inappropriate antibiotic had no effect on mortality . Early administration of broad-spectrum antimicrobials has always been stressed and advocated in surviving sepsis campaigns , however, evidence for this recommendation has been mainly provided in patients with septic shock [52–55].
In addition to inappropriate initial empirical antibiotic, our study did not show delayed time to appropriate antibiotic after fever onset as a predictor of mortality. This finding could be explained by an initial treatment selection bias. However, there are other studies that are unable to detect a mortality difference regarding timing of appropriate empirical therapy [32, 37]. When Lodise et al. looked at as to which patient subgroups would actually benefit greatest from timing of empirical antibiotics, they found that patients with severe disease benefitted most . Only a minority of the patients in our cohort had severe sepsis and the remaining majority of patients might have neutralized the impact of delayed appropriate antimicrobial treatment in that group. About 80 % of patients with SAB do not suffer from severe sepsis or septic shock . Patients with SAB caused by MRSA may be at increased mortality risk of being treated inadequately when MRSA is not covered in empiric antimicrobial regimens. However, community acquired MRSA is very rare in Turkey and the incidence of S. aureus infections is rapidly declining in Turkish ICUs . Due to all the reasons stated above, our study may not have shown significant differences in outcome between patients with early and delayed appropriate antimicrobial treatments.
Intensive care unit stay was one of the independent risk factors of mortality in our study. Either transit to an ICU  or the acquisition of SAB in the ICU  has been found to be independent predictors of mortality, probably since they were surrogate markers for infection severity.
In conclusion, the data from this prospective study performed in Turkish patients demonstrated several prognostic factors for SAB mortality including age, ICU stay and high CCI scores. Furthermore, methicillin resistance may be a risk factor for mortality of patients with SAB. In contrast, inappropriate initial empirical antibiotics and delays of starting the appropriate antibiotics within a few hours may not have any impact on mortality. In order to proper management of SAB, clinicians should be aware of patients with one or some of the above mentioned predictors.
MY ideated the study and conceived the data. MY and NE drafted manuscript; IIB and MY collected the study data from the participant centers; NE and HV analyzed and provided interpretation of the study data; MY, IIB, FA, AAB, MZB, MGG, SA, ADC, MAY, HB, MS, HA, FAA, IS, EA, SG, BC, RO, HL, and AM either followed the patients and/or performed the microbiological analyses in participant centers and gathered the study data. All authors read and approved the final manuscript.
The authors declare that they have no competing interests. A competing interest document has also been submitted with the abstract.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Keynan Y, Rubinstein E. Staphylococcus aureus bacteremia, risk factors, complications, and management. Crit Care Clin. 2013;29:547–62.View ArticlePubMedGoogle Scholar
- Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis. 1996;23:255–9.View ArticlePubMedGoogle Scholar
- Kern WV. Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges. Curr Opin Infect Dis. 2010;23:346–58.View ArticlePubMedGoogle Scholar
- Troidle L, Eisen T, Pacelli L, Finkelstein F. Complications associated with the development of bacteremia with Staphylococcus aureus. Hemodial Int. 2007;11:72–5.PubMedGoogle Scholar
- Fowler VG Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;293:3012–21.View ArticlePubMedGoogle Scholar
- Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Torok ME, et al. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis. 2011;11:208–22.View ArticlePubMedGoogle Scholar
- Atmaca O, Zarakolu P, Karahan C, Cakir B, Unal S. [Risk factors and antibiotic use in methicillin-resistant Staphylococcus aureus bacteremia in hospitalized patients at Hacettepe University Adult and Oncology Hospitals (2004–2011) and antimicrobial susceptibilities of the isolates: a nested case-control study]. Mikrobiyol Bul. 2014;48:523–37.View ArticlePubMedGoogle Scholar
- Akoglu H, Zarakolu P, Altun B, Unal S. [Epidemiological and molecular characteristics of hospital-acquired methicillin-resistant Staphylococcus aureus strains isolated in Hacettepe University Adult Hospital in 2004–2005]. Mikrobiyol Bul. 2010;44:343–55.PubMedGoogle Scholar
- Kizilarslanoglu MC, Sancak B, Yagci S, Hascelik G, Unal S. [Evaluation of methicillin-resistant Staphylococcus aureus bacteremia and comparison of prognosis according to vancomycin MIC values: experience of the last ten years]. Mikrobiyol Bul. 2013;47:199–210.View ArticlePubMedGoogle Scholar
- Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing—Twenty-first informational supplement document M100-S21 Wayne: CLSI; 2011.Google Scholar
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.View ArticlePubMedGoogle Scholar
- Soriano A, Martinez JA, Mensa J, Marco F, Almela M, Moreno-Martinez A, et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis. 2000;30:368–73.View ArticlePubMedGoogle Scholar
- Kim SH, Park WB, Lee KD, Kang CI, Kim HB, Oh MD, et al. Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin Infect Dis. 2003;37:794–9.View ArticlePubMedGoogle Scholar
- Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008;34:17–60.PubMed CentralView ArticlePubMedGoogle Scholar
- Culver DH, Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG, et al. Surgical wound infection rates by wound class, operative procedure, and patient risk index. National nosocomial infections surveillance system. Am J Med. 1991;91:152S–7S.View ArticlePubMedGoogle Scholar
- Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large U.S. database. Crit Care Med. 2006;34:2588–95.View ArticlePubMedGoogle Scholar
- Benfield T, Espersen F, Frimodt-Moller N, Jensen AG, Larsen AR, Pallesen LV, et al. Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin Microbiol Infect. 2007;13:257–63.View ArticlePubMedGoogle Scholar
- Jacobsson G, Dashti S, Wahlberg T, Andersson R. The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western Sweden. Scand J Infect Dis. 2007;39:6–13.View ArticlePubMedGoogle Scholar
- Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000–2006. J Infect Dis. 2008;198:336–43.View ArticlePubMedGoogle Scholar
- Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763–71.View ArticlePubMedGoogle Scholar
- van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012;25:362–86.PubMed CentralView ArticlePubMedGoogle Scholar
- Collignon P, Nimmo GR, Gottlieb T, Gosbell IB. Australian group on antimicrobial R. Staphylococcus aureus bacteremia, Australia. Emerg Infect Dis. 2005;11:554–61.PubMed CentralView ArticlePubMedGoogle Scholar
- Turnidge JD, Kotsanas D, Munckhof W, Roberts S, Bennett CM, Nimmo GR, et al. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust. 2009;191:368–73.PubMedGoogle Scholar
- Melzer M, Welch C. Thirty-day mortality in UK patients with community-onset and hospital-acquired meticillin-susceptible Staphylococcus aureus bacteraemia. J Hosp Infect. 2013;84(2):143–50.View ArticlePubMedGoogle Scholar
- Lamagni TL, Potz N, Powell D, Pebody R, Wilson J, Duckworth G. Mortality in patients with meticillin-resistant Staphylococcus aureus bacteraemia, England 2004–2005. J Hosp Infect. 2011;77:16–20.View ArticlePubMedGoogle Scholar
- Tacconelli E, Pop-Vicas AE, D’Agata EM. Increased mortality among elderly patients with meticillin-resistant Staphylococcus aureus bacteraemia. J Hosp Infect. 2006;64:251–6.View ArticlePubMedGoogle Scholar
- Kaech C, Elzi L, Sendi P, Frei R, Laifer G, Bassetti S, et al. Course and outcome of Staphylococcus aureus bacteraemia: a retrospective analysis of 308 episodes in a Swiss tertiary-care centre. Clin Microbiol Infect. 2006;12:345–52.View ArticlePubMedGoogle Scholar
- Kang CI, Song JH, Chung DR, Peck KR, Ko KS, Yeom JS, et al. Clinical impact of methicillin resistance on outcome of patients with Staphylococcus aureus infection: a stratified analysis according to underlying diseases and sites of infection in a large prospective cohort. J Infect. 2010;61:299–306.View ArticlePubMedGoogle Scholar
- Kang CI, Song JH, Ko KS, Chung DR, Peck KR. Asian network for surveillance of resistant pathogens study G. Clinical features and outcome of Staphylococcus aureus infection in elderly versus younger adult patients. Int J Infect Dis. 2011;15:e58–62.View ArticlePubMedGoogle Scholar
- Chen SY, Wang JL, Chen TH, Chiang WC, Wang JT, Chen SC, et al. Differences between methicillin-resistant Staphylococcus aureus bacteremic isolates harboring type IV and type V staphylococcal cassette chromosome mec genes based on prior patient healthcare exposure. Eur J Clin Microbiol Infect Dis. 2010;29:1539–46.View ArticlePubMedGoogle Scholar
- Wang FD, Chen YY, Chen TL, Liu CY. Risk factors and mortality in patients with nosocomial Staphylococcus aureus bacteremia. Am J Infect Control. 2008;36:118–22.View ArticlePubMedGoogle Scholar
- Fang CT, Shau WY, Hsueh PR, Chen YC, Wang JT, Hung CC, et al. Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome. J Antimicrob Chemother. 2006;57:511–9.View ArticlePubMedGoogle Scholar
- Guilarde AO, Turchi MD, Martelli CM, Primo MG. Staphylococcus aureus bacteraemia: incidence, risk factors and predictors for death in a Brazilian teaching hospital. J Hosp Infect. 2006;63:330–6.View ArticlePubMedGoogle Scholar
- Park SY, Son JS, Oh IH, Choi JM, Lee MS. Clinical impact of methicillin-resistant Staphylococcus aureus bacteremia based on propensity scores. Infection. 2011;39:141–7.View ArticlePubMedGoogle Scholar
- Perencevich EN. Excess shock and mortality in Staphylococcus aureus related to methicillin resistance. Clin Infect Dis. 2000;31:1311–3.View ArticlePubMedGoogle Scholar
- Gulmez D, Sancak B, Ercis S, Karakaya J, Hascelik G. [Investigation of SCCmec types and Panton-Valentine leukocidin in community-acquired and nosocomial Staphylococcus aureus strains: comparing skin and soft tissue infections to the other infections]. Mikrobiyol Bul. 2012;46:341–51.PubMedGoogle Scholar
- Ammerlaan H, Seifert H, Harbarth S, Brun-Buisson C, Torres A, Antonelli M, et al. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 western European countries. Clin Infect Dis. 2009;49:997–1005.View ArticlePubMedGoogle Scholar
- Topeli A, Unal S, Akalin HE. Risk factors influencing clinical outcome in Staphylococcus aureus bacteraemia in a Turkish university hospital. Int J Antimicrob Agents. 2000;14:57–63.View ArticlePubMedGoogle Scholar
- Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53–9.View ArticlePubMedGoogle Scholar
- Roghmann MC. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia. Arch Intern Med. 2000;160:1001–4.View ArticlePubMedGoogle Scholar
- Gould IM. MRSA bacteraemia. Int J Antimicrob Agents. 2007;30(Suppl 1):S66–70.View ArticlePubMedGoogle Scholar
- Wolkewitz M, Frank U, Philips G, Schumacher M, Davey P, Group BS. Mortality associated with in-hospital bacteraemia caused by Staphylococcus aureus: a multistate analysis with follow-up beyond hospital discharge. J Antimicrob Chemother. 2011;66:381–6.View ArticlePubMedGoogle Scholar
- Melzer M, Eykyn SJ, Gransden WR, Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis. 2003;37:1453–60.View ArticlePubMedGoogle Scholar
- Maor Y, Rahav G, Belausov N, Ben-David D, Smollan G, Keller N. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol. 2007;45:1511–4.PubMed CentralView ArticlePubMedGoogle Scholar
- van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011;55:405–10.PubMed CentralView ArticlePubMedGoogle Scholar
- Swenson JM, Anderson KF, Lonsway DR, Thompson A, McAllister SK, Limbago, et al. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol. 2009;47:2013–7.PubMed CentralView ArticlePubMedGoogle Scholar
- Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520–32.View ArticlePubMedGoogle Scholar
- Horino T, Sato F, Hosaka Y, Hoshina T, Tamura K, Nakaharai K, et al. Predictive factors for metastatic infection in patients with bacteremia caused by methicillin-sensitive Staphylococcus aureus. Am J Med Sci. 2015;349:24–8.PubMed CentralView ArticlePubMedGoogle Scholar
- Lesse AJ, Mylotte JM. Clinical and molecular epidemiology of nursing home-associated Staphylococcus aureus bacteremia. Am J Infect Control. 2006;34:642–50.View ArticlePubMedGoogle Scholar
- Chang FY, MacDonald BB, Peacock JE Jr, Musher DM, Triplett P, Mylotte JM, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Med (Baltimore). 2003;82:322–32.View ArticleGoogle Scholar
- Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580–637.View ArticlePubMedGoogle Scholar
- Fraser A, Paul M, Almanasreh N, Tacconelli E, Frank U, Cauda R, et al. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med. 2006;119:970–6.View ArticlePubMedGoogle Scholar
- Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003;31:2742–51.View ArticlePubMedGoogle Scholar
- Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest. 2003;123:1615–24.View ArticlePubMedGoogle Scholar
- Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–96.View ArticlePubMedGoogle Scholar
- Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003;36:1418–23.View ArticlePubMedGoogle Scholar
- Kaasch AJ, Rieg S, Kuetscher J, Brodt HR, Widmann T, Herrmann M, et al. Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study. Infection. 2013;41:979–85.View ArticlePubMedGoogle Scholar
- Erdem H, Dizbay M, Karabey S, Kaya S, Demirdal T, Koksal I, et al. Withdrawal of Staphylococcus aureus from intensive care units in Turkey. Am J Infect Control. 2013;41:1053–8.View ArticlePubMedGoogle Scholar
- van Hal SJ, Jones M, Gosbell IB, Paterson DL. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. PLoS One. 2011;6:e21217.PubMed CentralView ArticlePubMedGoogle Scholar